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Abstract 
Background 
Repeated episodes of limb ischaemia and reperfusion (remote ischaemic conditioning, 
RIC) may improve outcome after acute stroke.  
 
Methods 
We performed a pilot blinded placebo-controlled trial in patients with acute ischaemic 
stroke, randomised 1:1 to receive four cycles of RIC within 24 hours of ictus. The primary 
outcome was tolerability and feasibility. Secondary outcomes included safety, clinical 
efficacy (day 90), putative biomarkers (pre- and post-intervention, day 4) and exploratory 
haemodynamic measures. 
 
Findings 
Twenty-six patients (13 RIC, 13 sham) were recruited 15.8 hours (SD 6.2) post onset, age 
76·2 years (10.5), blood pressure 159/83mmHg (25/11) and NIHSS 5 [IQR 3.75-9.25]. RIC 
was well tolerated with 49/52 cycles completed in full. Three patients experienced vascular 
events in the sham group: two ischaemic strokes and two myocardial infarcts versus none 
in the RIC group (p=0·076, log-rank test). Compared to sham, there was a significant 
decrease in day 90 NIHSS in the RIC group, median NIHSS 1 [0.5-5] versus 3 [2-9.5], 
p=0.04; RIC augmented plasma heat shock protein (HSP) 27 (p<0·05, repeated 2-way 
ANOVA) and phosphorylated HSP27 (p<0·001) but not plasma S100-beta, matrix 
metalloprotinase-9, endocannabinoids or arterial compliance. 
 
Conclusions 
RIC after acute stroke is well tolerated and appears safe and feasible. RIC may improve 
neurological outcome and protective mechanisms may be mediated through HSP27. A 
larger trial is warranted. 
 
Clinical Trial Registration-URL: http://www.isrctn.com. Unique identifier: 
ISRCTN86672015 
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BACKGROUND 
Applying an ischaemic stimulus distant from the brain (remote ischaemic conditioning, 
RIC, e.g. transient limb ischaemia) after a stroke can induce neuroprotection.1 The 
mechanisms of action underlying this are unclear; the production of a chemical messenger 
released from the hypoxic limb has been implicated, e.g. nitric oxide, bradykinin, 
adenosine, heat-shock proteins and endocannabinoids.2, 3 RIC is an attractive prospect 
since it bears minimal cost and would be simple to administer. It may decrease stroke risk 
in patients with intracranial arterial stenosis and applying RIC in pre-hospital stroke 
patients is feasible.4, 5 Furthermore, preliminary studies of RIC in patients with acute 
myocardial infarction are encouraging.6 In the current study, we aimed to demontrate 
tolerability and feasibility of RIC in patients presenting to hospital with acute stroke whilst 
simultaneously investigating potential mechanisms of action. 
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METHODS 
Trial Design 
The REmote ischaemic Conditioning After Stroke Trial (RECAST) was a single-centre, 
randomised, outcome-blinded, placebo-controlled trial (ISRCTN 86672015). 
Subjects 
Adult patients with an ischaemic stroke in the last 24 hours causing arm and/or leg 
weakness were eligible. Exclusion criteria included modified Rankin Scale (mRS) >3, 
thrombolysis for index event and significant co-morbidity. Participants were recruited from 
Derby Teaching Hospitals NHS Foundation Trust, UK between March 2013 and July 2015.  
Randomisation and Intervention 
In addition to standard care (single antiplatelets, BP and cholesterol reduction), RIC was 
performed on the stroke unit immediately after randomisation (web-based, 1:1, minimised 
on age, sex, NIHSS and systolic BP). Intervention: 4 cycles of intermittent limb ischaemia; 
alternating 5 minutes inflation (20mmHg above systolic BP) and 5 minutes deflation 
performed manually using a standard upper arm blood pressure cuff in the non-paretic 
arm. Patient position was not specified. The control group received a sham procedure (cuff 
inflation to 30mmHg).  
Primary Outcome 
The primary outcome was tolerability and feasibility of RIC after acute ischaemic stroke. 
Secondary Outcomes 
Blood samples were collected (pre-RIC, post-RIC, day 4) for surrogate markers of efficacy 
(plasma S100-beta, MMP-9, troponin T), inflammation (C-reactive protein [CRP]) and other 
putative biomarkers (Heat Shock Proteins [HSP], endocannabinoids). Transcranial doppler 
(TCD) was performed as a continuous beat-to-beat recording during the intervention; 
central pressures measured with Sphygmocor.7 Serious adverse events (SAE), mRS, 
impairment (NIHSS, motricity index), Barthel Index, extended activities of daily living, Zung 
depression scale, and cognition (MMSE) were measured at day 90. Statistical tests are 
described in the respective tables/figures. 
Sample Size 
Assuming a meaningful delivery of RIC of at least three of the four 5-minute cycles, 26 
patients gives 90% power to reject the null hypothesis that intervention and sham are 
equally tolerated (SD 4 minutes and alpha=0.05). The original sample size was rounded to 
30 but with no losses to follow-up or cross-overs, recruitment was stopped at 26. 
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RESULTS 
26 participants were recruited over 27 months (Figure 1). All participants had an average 
age of 76 years; mean BP 159/83mmHg and median NIHSS 5 (Table 1). More participants 
in the control group had diabetes (5 vs 0, p=0·04, Fisher’s Exact test) and time to 
randomisation was 15·8 hours.  
Tolerability 
RIC was well tolerated: 49/52 cycles were completed in full. One participant was intolerant 
of RIC (due to cuff pressure), with an overall mean difference between groups of 46 
seconds (p=0·33). All patients tolerated the sham procedure. Eight (5 RIC, 3 sham) of 26 
participants correctly stated at day 90 the intervention they received at randomisation. 
Adverse events 
There were no procedure related SAEs (Supplementary Table I). Three patients 
experienced vascular events in the control group: two ischaemic strokes (day 6 and 8) and 
two myocardial infarcts in the same patient (day 1 and 66), versus none in the RIC group 
(p=0.076, log-rank test).   
Laboratory Measures 
In the RIC group, plasma analysis showed a significant increase in total HSP27 (p<0·05, 
repeated 2-way ANOVA) and phosphorylated HSP27 (pHSP27, p<0·001, Figure 2). HSPs 
60, 70 and 90 did not differ between groups or over time. Similarly, plasma CRP, S100-
beta, matrix metalloproteinase-9, troponin T and endocannabinoids did not differ between 
groups (Supplementary Figures I & II).  
Haemodynamic measures 
RIC did not significantly affect central blood pressure, mean arterial pressure, arterial 
compliance or Buckberg index (Supplementary Figure III). Most patients were ineligible for 
TCD assessment (AF n=11; proxy consent n=4, intolerant n=3; refusal n=1, no operator 
n=3, Supplementary Figure IV). 
Clinical outcomes 
Day 90 mRS was non-significantly lower in the treatment group (2 versus 3, p=0.8, 
Supplementary Table II). There was a significant decrease in day 90 NIHSS in the RIC 
group: median NIHSS 1 (interquartile range 0.5-4), versus 3 (1-4.5) (p=0.04 Mann-Whitney 
U test).  
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DISCUSSION 
The Remote Ischaemic Conditioning After Stroke Trial has demonstrated that RIC is well 
tolerated after acute stroke and appears safe and feasible. Furthermore, RIC may improve 
neurological outcome and reduce vascular event rates evidenced by a significant 
improvement in NIHSS and a trend to fewer vascular events by day 90. Biomarker studies 
suggest that protective mechanisms may be mediated through phosphorylated HSP27.  
There were no serious adverse events relating to RIC with only one patient reducing 
treatment due to cuff pressure intolerance. Pre-hospital RIC after acute stroke appears 
feasible but up to 18% of patients had a transportation time too short for 4 full cycles (the 
procedure was discontinued on arrival).4 The primary outcome, penumbral salvage, did not 
improve with RIC but there were more TIAs and less severe strokes on arrival to hospital 
in the per-conditioned group.4 The absence of baseline measurements and an imbalance 
at randomisation confounds interpretation of their results.  
Numerous messengers have been implicated in ischaemic conditioning, and we have 
demonstrated RIC causes a significant increase in serum total HSP27 and phosphorylated 
HSP27 (pHSP27) 4 days after intervention, compared to control. Human HSP27 is 
neuroprotective in experimental stroke and infarct volume reduction is enhanced if HSP is 
in a phosphorylated form.8 Pre-clinical models have shown benefit using RIC up to 6 hours 
post ictus1 but the role of RIC in the current trial is unlikely to be neuroprotective as the 
intervention was too late (16 hours). Inflammation post stroke is a process occurring over 
hours to days, hence, other potential mechanisms include reducing cerebral oedema1, 3 
and inducing ischaemic tolerance to recurrent events. Indeed, mice over-expressing HSP 
27 are protected against cerebral infarction.3 
This trial has a number of limitations. First, the sample size meant the trial was not 
powered to detect changes in clinical outcomes and the differences seen in neurological 
improvement and the trend to a reduction in vascular events may be due to chance or a 
greater cardiovascular risk in the control group. Second, participants receiving stroke 
thrombolysis were not included; the safety of running RIC in parallel with hyperacute 
stroke treatments requires further investigation, planned in the RECAST-2 trial, an ongoing 
pilot study (https://clinicaltrials.gov/ct2/show/NCT02779712). Finally, the longer-term 
effects of RIC are unknown and should be considered in future trial design; RIC may have 
both acute and more prolonged effects.9 
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Table 1. Baseline characteristics 
 
Characteristic RIC Sham 
 
n=13 n=13 
Age, years 74.7 (10.8) 77.7 (10.4) 
Male  8 (61.5) 9 (69.2) 
Blood pressure, mmHg 
  
Systolic 153.7 (18.9) 164.7 (29.6) 
Diastolic 81.5 (7.5) 84.3 (13.7) 
Heart rate 78.5 (13.1) 74.1 (17.3) 
ECG in AF 4 (30.8) 7 (53.8) 
NIHSS 6 [3.5,12] 5 [3.5,9.5] 
Premorbid mRS 0 [0,0.5] 0 [0,2] 
Time to randomisation, hours 16.3 (5.9) 15.3 (6.6) 
Clinical syndrome 
  
Lacunar 6 (46.2) 6 (46.2) 
Partial anterior circulation 3 (23.1) 2 (15.4) 
Total anterior circulation 4 (30.8) 4 (30.8) 
Posterior circulation 0 (0) 1 (7.7) 
Past Medical History  
  
Hypertension 5 (38.5) 9 (69.2) 
Hyperlipidaemia 5 (38.5) 7 (53.8) 
Diabetes mellitus 0 (0) 5 (38.5) 
Known AF 3 (23.1) 5 (38.5) 
Stroke 1 (7.7) 4 (30.8) 
TIA 2 (15.4) 1 (7.7) 
Ischaemic Heart Disease 2 (15.4) 5 (38.5) 
Peripheral Vascular Disease 0 (0) 1 (7.7) 
Data presented are mean (standard deviation), median [interquartile 
range] or number (percentage) 
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Figure Legends 
 
Figure 1. Trial Flow 
 
Figure 2. Effects of RIC vs sham on plasma levels of (A) Heat Shock Proteins (HSP) 
27, (B) phosphorylated HSP27, (C) HSP60, & (D) HSP70 (n=13 per group, ##p<0.01, 
*p<0.05, ***p<0.001, repeated measures ANOVA with adjustment using Dunnett’s 
multiple comparisons test, where * denotes a difference between groups, #denotes a 
difference over time). Data presented are mean ± SEM. 
 
Assessed for eligibility (n= 1850) 
Excluded  (n=1824) 
•  Not meeting inclusion criteria (n=1769) 
•  Declined to participate (n=11) 
•   Other reasons (n=44, see suppl Table 1) 
Analysed  (n=13) 
   Excluded from analysis (n=0 ) 
Lost to follow-up (n= 0) 
Allocated to RIC (n=13) 
•    Received allocated intervention (n=13 ) 
•  Did not receive RIC  (n=0) 
•  Partial RIC (n=1, cuff intolerance) 
Lost to follow-up (n=0) 
  
Allocated to sham (n=13) 
•  Received sham (n=13) 
•  Did not receive sham  (n=0) 
Analysed  (n=13) 
   Excluded from analysis (n=0) 
  
Randomised (n=26) 
Enrollment 
Analysis 
Follow up 
Allocation 
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REMOTE ISCHAEMIC CONDITIONING AFTER STROKE TRIAL (RECAST): 
Supplementary Material 
 
 
Statistical Methods 
RIC and control groups were compared using appropriate statistical tests (SPSS Statistics 
version 22): binary data with chi-squared, Fisher’s Exact test or logistic regression with 
adjustment of baseline prognostic factors; continuous data are compared using t-test and 
ANCOVA with adjustment for baseline covariates. Repeated and mixed measures ANOVA 
was used to compare biomarkers, SyphgmoCor and TCD analyses at multiple time-points 
and between groups, with adjustment using Dunnett’s multiple comparisons test (Prism 6 
for Mac OS X version 6·0f). Data in the figures are mean values ± SEM unless otherwise 
stated. 
 
 
 
 
Supplementary Table I 
 
Serious adverse events (SAE) RIC (n=13) Sham (n=13) p* 
No with SAE 4 (30.8) 7 (53.8) 0.23 
    Non-fatal 4 (30.8) 7 (53.8) 0.23 
    Fatal 0 (0) 0 (0)  
No with vascular events 0 (0) 3 (23.1) 0.22 
    No with non-fatal stroke 0 (0) 2 (15.4) ∂ 0.48 
    No with non-fatal MI 0 (0) 1 (7.7) † 1 
    Venous thromboembolism 0 (0) 0 (0)   
 ∂ Occurred on day's 6 and 8 post randomisation in different patients  
† Same patient suffered 2 x NSTEMI on day 1 and day 66 post randomisation 
* Analysed using Fisher's Exact test   
The data monitoring committee assessed unblinded data (planned) halfway through the trial and, 
whilst there were no procedure related adverse events, deemed it unnecessary to include patients 
having received thrombolysis. 
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Supplementary Table II  
Comparison of the RIC and sham treated groups with respect to clinical outcome measures at day 90 
 
Functional measures (day 90) RIC Sham Unadjusted values Adjusted values* 
 (n=13) (n=13) Mean difference 
(95% CI) 
p Mean difference 
95% CI 
p 
Modified Rankin Scale (/6)       
Mean 2.46 (1.39) 2.69 (1.79) -0.23 (-1.5, 1.1) 0.72 -0.12 (-0.87, 1.1) 0.82 
Median 2 [1, 4] 3 [1, 4.5]  0.8   
Barthel Index (/100)       
Mean 69.6 (35.6) 62.3 (41.0) 7.3 (-23.7, 38.4) 0.63 4.9 (-28.7, 18.8) 0.67 
Median 85 [25, 100] 85 [17.5, 100]  0.84   
NIHSS       
Mean 2.7 (3.0) 6.1 (5.6) -3.4 (-7.0, 0.26) 0.067 -3.5  (-6.3, -0.7) 0.016 
Median 1 [0.5, 5] 3 [2, 9.5]  0.044   
Motricity Index (/100)       
Mean 74.9 (30.7) 64.5 (39.2) 10.4 (-18.6, 39.4) 0.47 8.9 (-12.5, 30.3) 0.4 
Median 89 [61, 100] 74 [32.5, 100]  0.85   
NEADL (/66)       
Mean 36.6 (23.7) 24.5 (23.1) 12.1 (-6.9, 31) 0.2 10.8 (-1.8, 23.4) 0.09 
Median 41 [6.5, 58] 28 [3.5, 47]  0.08   
Zung depression score       
Mean 49.0 (20.1) 55.4 (12.7) -6.4 (-20.4, 7.6) 0.36 -4.1 (-9.6, 1.6) 0.15 
Median 52.5 [30, 65] 55 [48.1, 64.4]  0.41   
Mini-Mental State Examination†       
Mean 26.5 (3.3) 23.2 (5.7) 3.3 (-0.6, 7.1) 0.09 3.1 (-0.7, 7) 0.11 
Median 27 [25.5, 28.5] 25 [19, 27]    0.12 
 
 
Data are mean (SD) or median [IQR].  
* Adjusted for age & stroke severity (NIHSS), analysis by ANCOVA (analysis of covariance). Median values are compared using a Mann-Whitney 
U test. 
† One patient in the sham group unable to complete MMSE due to aphasia; Data presented are mean values (standard deviation) 
NIHSS, National Institutes of Health Stroke Scale; NEADL, Nottingham Extended Activities of Daily Living 
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Supplementary Figure I 
Effects of RIC vs sham on plasma levels of protein S100-beta, matrix metalloproteinase 9 
(MMP-9), Troponin-T and C-reactive protein (CRP). Analysis by repeated measures 
ANOVA did not reveal a difference over time or between groups (n= 13 per group, data are 
mean ± SEM). Assays were performed blinded by Luminex technology using commercially 
available assays (Merck Millipore Ltd, UK). 
 
 
 
 
 
 
 
 
  
pre po
st
da
y 4
-0.10
-0.05
0.00
0.05
0.10
Troponin T
D
el
ta
 c
ha
ng
e,
 n
g/
m
l
RIC
Sham
pr
e
po
st
da
y 4
0
500
1000
S100-beta
D
el
ta
 c
ha
ng
e,
 p
g/
m
l
RIC
Sham
pr
e
po
st
da
y 4
-500
0
500
1000
CRP
D
el
ta
 c
ha
ng
e,
 p
g/
m
l
RIC
Sham
pr
e
po
st
da
y 4
-100
0
100
200
300
400
MMP-9
D
el
ta
 c
ha
ng
e,
 n
g/
m
l
RIC
Sham
 4 
Supplementary Figure II: Effects of RIC vs sham on plasma levels of endocannabinoids 
(A) anandamide (AEA), (B) oleoylethanolamide (OEA), (C) palmitoylethanolamide (PEA) 
and (D) 2-arachidonoylglycerol (2-AG) (n=11 RIC, 13 Sham, #### p<0.0001, ### p<0.001, 
repeated measures ANOVA with adjustment using Dunnett’s multiple comparisons test, 
where # denotes a difference over time). Data presented are mean ± SEM. eCBs were 
measured by liquid chromatography- tandem mass spectrometry based on a validated 
method.1 
 
 
 
 
1. Richardson D, Ortori CA, Chapman V, Kendall DA, Barrett DA. Quantitative profiling of endocannabinoids 
and related compounds in rat brain using liquid chromatography-tandem electrospray ionization mass 
spectrometry. Anal Biochem. 2007;360:216-226 
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Supplementary Figure III 
The effects of RIC vs sham on central blood pressure ((A) systolic, (B) diastolic, (C) mean 
arterial (MAP)), (D) arterial compliance (Augmentation index) and (E) Buckberg index. Data 
are mean ± SEM. (SyphgmoCor analyses at multiple time-points and between groups, with 
adjustment using Dunnett’s multiple comparisons test) 
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Supplementary Figure IV 
The effects of upper limb RIC or sham on ipsilateral middle cerebral artery blood flow. The values represent the mean value 
(±standard deviation) taken from continuous beat-to-beat recording over each inflation/deflation cycle (sham n=2, RIC n=2) 
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